Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech News -- Ignore unavailable to you. Want to Upgrade?

To: kenhott who wrote (6040)	3/27/2008 9:36:02 AM
From: dr.praveen	Read Replies (1) \| Respond to of 7143

Here you go...!!!The problems never seem to end. PS: No position luckily:-) reuters.com UPDATE 1-SGX Pharma: Toxicity seen in 2 trials of cancer drug Thu Mar 27, 2008 7:50am EDT March 27 (Reuters) - SGX Pharmaceuticals Inc (SGXP.O: Quote, Profile, Research) said it observed toxicity related to dosing levels in two early-stage trials of its lead experimental cancer drug, earlier than expected. The toxicity was of a nature that was not anticipated based on the pre-clinical profile of the drug, SGX523, the company said in a statement. Typically, drugs in pre-clinical trials are tested on animals, and if the drug proves to be safe and effective, clinical trials on humans may be conducted. SGX said patients continue to be treated in one of the two trials that involves dosing for a continuous 28-day cycle. This trial, however, is testing a lower dose of the drug than the other trial. SGX is evaluating the safety and effectiveness of treatment at this dose. No patients are currently being treated in the other trial, which was designed to examine interrupted dosing, a repeating 21-day cycle of 14 days on therapy followed by seven days off, the company said in a statement. SGX, based in San Diego, is developing at least three other compounds for various cancers, none of which are currently in the clinical testing stage. Shares of the company closed at $4 Wednesday on Nasdaq.